SecBot SecBot

INDV

Supernus, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001625297 Biotech & Drug Discovery
Former ticker of Supernus, Inc. · SUPN stock page →
No price
Market cap
$4.2B
Mid cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$50.00
range $45.00–53.00
Short interest
9.41M
≈8.0% of shares · −9.6%
Days to cover
3.4
at average volume
Insider net
−$2.7M
3 buyers · 2 sellers · 12 mo
New fund stakes
2
Q2 2026 13F · 3 exits
Filing reports
28
analyzed by SecBot
SecBot read BULLISH 15 reports · 90 days
Balance 0 bearish · 3 bullish · 12 neutral oldest → newest, height = score
Avg score ·High conf. 12/15
Strongest NEUTRAL Indivior Pharmaceuticals completed its merger with Supernus Pharmaceuticals on November 2, 2026, with…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders bought $139.2K at an average $34.98. 2 insiders sold $2.8M.

  • InstitutionsBULLISH

    Q2 2026: 38 added (2 new), 25 trimmed or exited. Largest new: Assenagon Asset Management S.A $63.2M, Westfield Capital Management $42.7M.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate $1.055 → $1.220 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −9.6% to 9.41M shares. 3.4 days to cover, ≈8.0% of shares.

Who's buying

13F· Q2 2026
2
new positions
3
exits
$105.9M
in new stakes
FundMoveSharesValue
CITADEL ADVISORS LLCTRIM2,667,827$109.5M
MILLENNIUM MANAGEMENT LLCTRIM2,098,945$86.1M
DIMENSIONAL FUND ADVISORS LPADD1,896,605$77.8M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPTRIM1,642,086$67.4M
Assenagon Asset Management S.A.NEW1,540,928$63.2M
Point72 Asset Management, L.P.DOUBLED1,250,639$51.3M
UBS Group AGTRIM1,160,618$47.6M
WESTFIELD CAPITAL MANAGEMENT CO LPNEW1,041,191$42.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy3Buy6Hold1Sell0Strong Sell0
Recent actions
DateFirmActionRating
Nov 4, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Oct 28, 2026Barclays
MAINTAIN
MAINTAINOverweight
Aug 5, 2026Barclays
MAINTAIN
MAINTAINOverweight
Jun 18, 2026Barclays
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$139.2K
bought · 3 insiders
$2.8M
sold · 2 insiders
DateInsiderTypeValue
Aug 27, 2026
Anderson Woodrow D
Chief Accounting Officer
Aug 27, 2026
BUY$53.5K
Aug 5, 2026
Anderson Woodrow D
Chief Accounting Officer
Aug 5, 2026
BUY$54.4K
Jul 10, 2026
Heidbreder Christian
Chief Scientific Officer
Jul 10, 2026
SELL$764.6K
Jun 22, 2026
Ciaffoni Joseph
Chief Executive Officer
Jun 22, 2026
EXERCISE1,266,903 sh
Jun 22, 2026
Ciaffoni Joseph
Chief Executive Officer
Jun 22, 2026
TAX W/H$23.5M
Jun 11, 2026
Heidbreder Christian
Chief Scientific Officer
Jun 11, 2026
SELL$707.4K
Jun 8, 2026
Preblick Ryan
Chief Financial Officer
Jun 8, 2026
SELL$1.4M
May 13, 2026
Wheadon David E.
Director
May 13, 2026
AWARD10,430 sh

Earnings setup

Estimates
$1.22
EPS estimate, this quarter
+16%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$1.22$1.22–$1.22+0.5%$337.9M
Next Q$0.94$0.86–$1.02-12.7%$328.0M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
9,414,157
shares short
-9.6%
vs prior settlement
3.4
days to cover
≈8.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 3, 2026 SEC
Supernus reported that due to a Special Dividend declared on September 16, 2026, the conversion rate on its 0.625%…
8-K · Impact 2/10
Nov 3, 2026 Listing status
Delisted: INDV, removed from the Nasdaq symbol directory
Indivior Pharmaceuticals, Inc. - Common Stock
Nov 2, 2026 SEC
Indivior Pharmaceuticals completed its merger with Supernus Pharmaceuticals on November 2, 2026, with Supernus…
8-K · Impact 5/10
Oct 29, 2026 SEC
Indivior reported record Q3 2026 results with total net revenue up 13% YoY to $356M, record SUBLOCADE revenue up 22%…
425 · Impact 5/10
Sep 22, 2026 Event
HSR Early Termination: Indivior Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Indivior
Sep 17, 2026 Press
Indivior declared a special cash dividend of $8.13 per share, contingent on the closing of its previously announced…
Impact 4/10
Aug 27, 2026 Insider
Anderson Woodrow D bought 1,500 shares
Chief Accounting Officer @ $35.69 ($53.5K)
Aug 5, 2026 Insider
Anderson Woodrow D bought 1,500 shares
Chief Accounting Officer @ $36.28 ($54.4K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 3, 2026
Listing
Delisted: INDV, removed from the Nasdaq symbol directory
Indivior Pharmaceuticals, Inc. - Common Stock
Oct 29, 2026
Earnings
Indivior Reports Third Quarter 2026 Financial Results
RICHMOND, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the third…
Oct 29, 2026
Earnings result
INDV Q3 2026 Earnings: EPS $1.32 (+15.6% vs est)
Oct 19, 2026
Earnings
Indivior to Report Third Quarter 2026 Financial Results
RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter…
Sep 22, 2026
Enforcement
HSR Early Termination: Indivior Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Indivior Pharmaceuticals, Inc.; Supernus Pharmaceuticals,

SecBot reports

28 filings · 3 press releases · 9 bullish · 0 bearish · 19 neutral
All INDV filing & press-release reports (31)